The Phase Ib trial is set to test a gene therapy designed to target a rare disorder that causes muscle and respiratory failure.

Evotec receives grant from Korean Government to develop novel antibody-based treatments for lung diseases: Hamburg, Germany Thursday, January 23, 2025, 10:00 Hrs [IST] Evotec SE, ...

Stealth BioTherapeutics Announces PDUFA Action Date Extension for Elamipretide to Treat Patients with Barth Syndrome ...

Aro Biotherapeutics, a clinical-stage biotechnology company working to develop potent and tissue-targeted medicines, today announced the dosing of the first patient in its clinical trial of ABX1100, a ...

Xenon gas, currently used in medicine as an anesthetic and neuroprotective agent for treating brain injuries, showed potential in protecting the brain in studies.

Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for ...

The Covid-19 outbreak in 2020 was on a scale not seen since the Spanish flu pandemic in 1918 and laid bare our lack of ...

Zydus Lifesciences added 1.10% to Rs 987.60 after the company said that the USFDA had granted orphan drug designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic ...

Zydus’ Usnoflast receives US FDA orphan drug designation to treat amyotrophic lateral sclerosis: Our Bureau, Mumbai Thursday, January 23, 2025, 12:15 Hrs [IST] Zydus, a leading, ...

GOTHENBURG, SE / ACCESS Newswire / January 23, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, January 23, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company dis ...

Pulmonary fibrosis is a rare, chronic disease that causes scarring in the lungs, making breathing difficult for people who suffer with it. And, as University of South Florida pulmonologist Dr. Jose ...

The SNU BioTalk 2025 an International Conference, themed "Symphony of Cellular Signals in Metabolism and Immune Response," ...